Erdafitinib and Vfend (Voriconazole Suspension)
Determining the interaction of Erdafitinib and Vfend (Voriconazole Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 may increase the plasma concentrations and risk of toxicity of erdafitinib, which is a substrate of these isoenzymes. When coadministered with fluconazole, a strong CYP450 2C9 inhibitor and moderate CYP450 3A4 inhibitor, erdafitinib mean ratios for Cmax and AUC were 121% and 148%, respectively, relative to erdafitinib alone. Similarly, when coadministered with itraconazole, a strong CYP450 3A4 inhibitor, erdafitinib mean ratios for Cmax and AUC were 105% and 134%, respectively, relative to erdafitinib alone. MANAGEMENT: Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided. If concomitant use is unavoidable, patients should be closely monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring of erdafitinib should be considered whenever a CYP450 2C9 or 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Professional:GENERALLY AVOID: Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 may increase the plasma concentrations and risk of toxicity of erdafitinib, which is a substrate of these isoenzymes. When coadministered with fluconazole, a strong CYP450 2C9 inhibitor and moderate CYP450 3A4 inhibitor, erdafitinib mean ratios for Cmax and AUC were 121% and 148%, respectively, relative to erdafitinib alone. Similarly, when coadministered with itraconazole, a strong CYP450 3A4 inhibitor, erdafitinib mean ratios for Cmax and AUC were 105% and 134%, respectively, relative to erdafitinib alone.
MANAGEMENT: Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided. If concomitant use is unavoidable, patients should be closely monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring of erdafitinib should be considered whenever a CYP450 2C9 or 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Generic Name: voriconazole
Brand name: Vfend, Vfend
Synonyms: Vfend, Vfend Injection
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erdafitinib-Vfend (Voriconazole Tablets)
- Erdafitinib-Vfend I.V.
- Erdafitinib-Vfend Injection
- Erdafitinib-Vfend Oral
- Erdafitinib-VFEND oral/injection
- Erdafitinib-Vfend Tablets
- Vfend (Voriconazole Suspension)-Erelzi Prefilled Syringe
- Vfend (Voriconazole Suspension)-Erelzi Sensoready Pen
- Vfend (Voriconazole Suspension)-Erelzi Subcutaneous
- Vfend (Voriconazole Suspension)-Ergocalciferol
- Vfend (Voriconazole Suspension)-Ergocalciferol Capsules and Tablets
- Vfend (Voriconazole Suspension)-Ergocalciferol Solution